PMID- 31964467
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20200617
IS  - 1976-670X (Electronic)
IS  - 1976-6696 (Print)
IS  - 1976-6696 (Linking)
VI  - 53
IP  - 2
DP  - 2020 Feb
TI  - PEP-1-GLRX1 protein exhibits anti-inflammatory effects by inhibiting the 
      activation of MAPK and NF-kappaB pathways in Raw 264.7 cells.
PG  - 106-111
AB  - Glutaredoxin 1 (GLRX1) has been recognized as an important regulator of redox 
      signaling. Although GLRX1 plays an essential role in cell survival as an 
      antioxidant protein, the function of GLRX1 protein in inflammatory response is 
      still under investigation. Therefore, we wanted to know whether transduced 
      PEP-1-GLRX1 protein inhibits lipopolysaccharide (LPS)- and 12-O-tetradecanoyl 
      phorbol-13-acetate (TPA)-induced inflammation. In LPS-exposed Raw 264.7 cells, 
      PEP-1-GLRX1 inhibited cyclooxygenase-2 (COX-2), inducible nitric oxide synthase 
      (iNOS), activation of mitogen activated protein kinases (MAPKs) and nuclear 
      factor-kappaB (NF-kappaB) expression levels. In a TPA-induced mouse-ear edema model, 
      topically applied PEP-1-GLRX1 transduced into ear tissues and significantly 
      ameliorated ear edema. Our data reveal that PEP-1-GLRX1 attenuates inflammation 
      in vitro and in vivo, suggesting that PEP-1-GLRX1 may be a potential therapeutic 
      protein for inflammatory diseases. [BMB Reports 2020; 53(2): 106-111].
FAU - Shin, Min Jea
AU  - Shin MJ
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252, Korea.
FAU - Kim, Dae Won
AU  - Kim DW
AD  - Department of Biochemistry and Molecular Biology, Research Institute of Oral 
      Sciences, College of Dentistry, Gangneung-Wonju National University, Gangneung 
      25457, Korea.
FAU - Choi, Yeon Joo
AU  - Choi YJ
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252, Korea.
FAU - Cha, Hyun Ju
AU  - Cha HJ
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252, Korea.
FAU - Lee, Sung Ho
AU  - Lee SH
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252; Genesen Inc., Seoul 06181, 
      Korea.
FAU - Park, Jinseu
AU  - Park J
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252, Korea.
FAU - Han, Kyu Hyung
AU  - Han KH
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252, Korea.
FAU - Eum, Won Sik
AU  - Eum WS
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252, Korea.
FAU - Choi, Soo Young
AU  - Choi SY
AD  - Department of Biomedical Science and Research Institute of Bioscience and 
      Biotechnology, Hallym University, Chuncheon 24252, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - BMB Rep
JT  - BMB reports
JID - 101465334
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Glutaredoxins)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Pep-1 peptide)
RN  - 0 (Peptides)
RN  - 5UX2SD1KE2 (Cysteamine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Cyclooxygenase 2/metabolism
MH  - Cyclooxygenase 2 Inhibitors/pharmacology
MH  - Cysteamine/*analogs & derivatives
MH  - Edema/chemically induced/metabolism/therapy
MH  - Glutaredoxins/*pharmacology
MH  - Inflammation/*metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Mitogen-Activated Protein Kinases/*antagonists & inhibitors/metabolism
MH  - NF-kappa B/*metabolism
MH  - Nitric Oxide Synthase Type II/antagonists & inhibitors/metabolism
MH  - *Peptides
MH  - Phosphorylation
MH  - RAW 264.7 Cells
MH  - Signal Transduction/drug effects
MH  - Tetradecanoylphorbol Acetate/pharmacology
PMC - PMC7061214
COIS- CONFLICTS OF INTEREST The authors have no conflicting interests.
EDAT- 2020/01/23 06:00
MHDA- 2020/06/18 06:00
PMCR- 2020/02/29
CRDT- 2020/01/23 06:00
PHST- 2019/07/15 00:00 [received]
PHST- 2020/01/23 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2020/01/23 06:00 [entrez]
PHST- 2020/02/29 00:00 [pmc-release]
AID - 4702 [pii]
AID - BMB-53-106 [pii]
AID - 10.5483/BMBRep.2020.53.2.180 [doi]
PST - ppublish
SO  - BMB Rep. 2020 Feb;53(2):106-111. doi: 10.5483/BMBRep.2020.53.2.180.